Lantheus Holdings, Inc. (NASDAQ:LNTH) Stock Position Lessened by Moody National Bank Trust Division

Moody National Bank Trust Division lowered its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 5.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 14,769 shares of the medical equipment provider’s stock after selling 915 shares during the quarter. Moody National Bank Trust Division’s holdings in Lantheus were worth $1,321,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of LNTH. Janus Henderson Group PLC increased its stake in shares of Lantheus by 7.7% during the third quarter. Janus Henderson Group PLC now owns 3,588,571 shares of the medical equipment provider’s stock valued at $393,844,000 after acquiring an additional 257,022 shares during the period. Farallon Capital Management LLC boosted its stake in Lantheus by 53.7% during the second quarter. Farallon Capital Management LLC now owns 2,279,227 shares of the medical equipment provider’s stock valued at $182,999,000 after buying an additional 796,000 shares in the last quarter. Geode Capital Management LLC grew its holdings in Lantheus by 2.0% during the third quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock worth $184,798,000 after acquiring an additional 32,551 shares during the period. Reinhart Partners LLC. raised its position in Lantheus by 9.9% in the fourth quarter. Reinhart Partners LLC. now owns 1,366,873 shares of the medical equipment provider’s stock worth $122,280,000 after acquiring an additional 123,282 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in Lantheus by 1.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,239,502 shares of the medical equipment provider’s stock valued at $99,525,000 after acquiring an additional 19,071 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Analyst Upgrades and Downgrades

LNTH has been the topic of a number of research reports. Truist Financial reiterated a “buy” rating and issued a $120.00 target price (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. The Goldman Sachs Group started coverage on Lantheus in a research note on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective for the company. Finally, JMP Securities cut their target price on Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a research report on Thursday, November 7th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $131.86.

Lantheus Stock Down 1.3 %

Shares of NASDAQ:LNTH opened at $94.65 on Tuesday. The company’s fifty day moving average is $90.39 and its two-hundred day moving average is $99.69. The company has a market cap of $6.58 billion, a P/E ratio of 15.75 and a beta of 0.46. Lantheus Holdings, Inc. has a 12-month low of $50.20 and a 12-month high of $126.89.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.